Last year, the European Medicines Agency (EMA) approved a pivotal phase IIb/III clinical trial evaluating AT-001 for the treatment of Hereditary Cystatin C Amyloid Angiopathy (HCCAA), a rare form ...

PARIS, France I February 12, 2025 I GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and ...

THE government is seeking a US$5,31 million grant from the African Development Bank (AfDB) to support the development of the beef and leather value chain. The support is part of the Zimbabwe ...

Sisterly love is universal, and these stepsisters aren't afraid to show it. Here are some of the best stepsisters in anime!

The global active pharmaceutical ingredients market size was worth USD 239.18 billion in 2024 and is expected to reach around USD 368.49 billion by 2033, with a noteworthy CAGR of 5.64% from 2023 to ...

The NSE Nifty 50 ended 42.95 points or 0.18% down at 23,696.30 and the BSE Sensex closed 312.53 points or 0.40% lower at ...

DKR Engineering’s No. 3 crew of Laurents Hoerr, Job van Uitert and Georgios Kolovos came home second, 11.342 seconds behind, ...

NTLA-2002 is aiming to be a long-lasting or life-long gene therapy indicated for curing hereditary angioedema ... Intellia and over 80% for Editas. The 5-year total returns for Intellia resulted ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

as the EMA launched a review in July after reports of fatalities in clinical trials. Prior to Oxbryta's approval, doctors could only treat the symptoms of the inherited blood disorder, which ...